Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 55.2%

Neg 0% Neu 0% Pos 55.2%

Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.